Vinge advises Procuritas Capital Investor VII (“Procuritas”) in connection with its acquisition of PropTech Sweden AB (“PropTech Sweden”) and its subsidiaries Axcell Fastighetspartner AB (“Axcell Fastighetspartner AB”) and Ömangruppen Svenska AB (“Ömangruppen”).

PropTech Sweden is the parent company of Ömangruppen and Axcell Fastighetspartner, two leading companies in indoor climate, energy efficiency, and property management. With over 300 employees and 30 local offices in southern Sweden, Luleå and Örnsköldsvik, the group acts as a close partner to property owners who want to increase energy efficiency or optimize the operation of their property in other ways. Procuritas has since its founding in 1986 completed more than 50 investments and hundreds of add-on acquisitions in the Nordic region. As real estate accounts for 40% of Sweden's total energy consumption, Procuritas considers PropTech Sweden a vital player in the climate transition, especially in view of upcoming EU regulations on reduced emissions. Completion of the acquisition is subject to customary competition clearance.

Vinge’s team mainly consisted of Jonas JohanssonMaria Dahlin Kolvik, Clara Sohlberg, Eskil Nyström (M&A), Karl-Gustaw Tobola (Banking and Finance), Daniel Prawitz, Mario Saad, Clara Klingspor (Corporate Commercial), Julia Löfqvist (Compliance), Petronella Hallberg, Amelia Rihs (Employment) Lina Österberg (Environment), Mathilda Persson, Alva Skott (IT & GDPR), Alexandra Tamm (Real Estate), Kristoffer Sällfors (Public Procurement) and Johan Walhbom (EU, Competition and Regulatory).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026